Lilly Moves Ahead With Retevmo Launch In A Challenging Environment

The company secured FDA approval for selpercatinib in RET-driven NSCLC and thyroid cancer, months ahead of the PDUFA date. Oncology president Anne White talked to Scrip about the launch. 

FDA approved background, 3D rendering, blue street sign
Lilly will launch the RET inhibitor despite coronavirus-related limitations

Eli Lilly & Co. will immediately make Retevmo (selpercatinib) available to patients after securing US Food and Drug Administration approval on 8 May for the RET inhibitor in certain cancers driven by rearranged during transfusion (RET) alterations. Lilly Oncology president Anne White said in an interview that given the critical nature of the treatment, the company will launch the drug immediately despite the challenging commercial dynamics caused by the COVID-19 pandemic.

Retevmo was approved by FDA for adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced metastatic RET-mutant medullary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip